ArticleMicrobiologyOpen2019
Efficacy of levofloxacin against biofilms of Pseudomonas aeruginosa isolated from patients with respiratory tract infections in vitro.
Article in MicrobiologyOpen, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 23 citations in OpenAlex.
- Repurposing Ponatinib Hydrochloride as an Antibacterial and Antibiofilm Agent Against Multidrug-ResistantMicroorganisms · 2026Article
- Comprehensive safety and toxicity analysis of 2,2'-Bipyridine derivatives in combating MRSA biofilm formation and persistence.Frontiers in cellular and infection microbiology · 2025Article
- Ketoprofen attenuates Las/Rhl quorum-sensing (QS) systems of Pseudomonas aeruginosa: molecular and docking studies.Molecular biology reports · 2024Article
- Subinhibitory concentrations of antibiotics affect development and parameters ofFrontiers in pharmacology · 2024Article
- In vitro and in silico assessment of anti-quorum sensing activity of Naproxen against Pseudomonas aeruginosa.World journal of microbiology & biotechnology · 2023Article
- Inhibitory effects of simeprevir onZhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2023Article
- Effect of Berberine and Blue LED Irradiation on Combating Biofilm of Pseudomonas aeruginosa and Staphylococcus aureus.Current microbiology · 2022Article
- Sub-Inhibitory Antibiotic Exposure and Virulence inAntibiotics (Basel, Switzerland) · 2021Review
- Quinolone Resistance ofInternational journal of molecular sciences · 2021Article
- Dynamic Adaptive Response ofAntibiotics (Basel, Switzerland) · 2021Article
- Antimicrobial, Antibiofilm, and Anti-persister Activities of Penfluridol AgainstFrontiers in microbiology · 2021Article
- Repurposing Antispasmodic Agent Otilonium Bromide for Treatment ofFrontiers in microbiology · 2020Article
- Article
- Efficacy of levofloxacin against biofilms of Pseudomonas aeruginosa isolated from patients with respiratory tract infections in vitro.MicrobiologyOpen · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microbial biofilms are formed in a variety of clinical situations and increase antibiotic resistance of the pathogen by almost ~1,000 times. The effect of levofloxacin (OFLX) on the biofilms of Pseudomonas aeruginosa strain PAO1 and the clinical isolates was investigated by crystal violet staining and confocal laser scanning microscope. The transcriptional alteration in the PAO1 biofilms upon OFLX treatment was also analyzed by RNA sequencing (RNA-seq). We found that while OFLX significantly inhibited P. aeruginosa biofilm formation in a dose-dependent manner, it could not completely eradicate preformed biofilms even at higher concentrations. RNA-seq revealed that PAO1 genes related to metabolism, formation of secondary metabolites, and quorum sensing biosynthesis were differentially expressed in the biofilms treated with OFLX. Our data might be useful in determining the optimum OFLX concentration needed for P. aeruginosa biofilm inhibition and eradication in patients with respiratory tract infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.